1. Home
  2. KG vs ACET Comparison

KG vs ACET Comparison

Compare KG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KG

Kestrel Group Ltd.

N/A

Current Price

$7.37

Market Cap

87.3M

Sector

Finance

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$9.54

Market Cap

83.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KG
ACET
Founded
N/A
1947
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.3M
83.3M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
KG
ACET
Price
$7.37
$9.54
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
22.1K
74.1K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
1819.15
N/A
EPS
N/A
N/A
Revenue
$34,049,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
785.08
N/A
52 Week Low
$6.72
$0.46
52 Week High
$29.13
$9.97

Technical Indicators

Market Signals
Indicator
KG
ACET
Relative Strength Index (RSI) 43.02 58.39
Support Level N/A $7.45
Resistance Level $8.17 $9.59
Average True Range (ATR) 0.53 0.52
MACD 0.04 0.05
Stochastic Oscillator 46.79 66.67

Price Performance

Historical Comparison
KG
ACET

About KG Kestrel Group Ltd.

Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: